Amgen: Sandoz Seeks To Circumvent Biosimilars Law
This article was originally published in Scrip
Executive Summary
Amgen Inc. has filed another lawsuit involving the Biologics Price Competition and Innovation Act (BPCIA) at the US District Court for the District of New Jersey against Novartis AG unit Sandoz Inc., accusing the biosimilar maker again of violating certain aspects of the law's patent-dispute-resolution provisions – commonly called the patent dance.